
Boston Scientific to Acquire Penumbra for $14.5 Billion, Expanding Stroke Tech
Boston Scientific signed a cash-and-stock deal to acquire Penumbra for about $14.5 billion, valuing Penumbra at $374 per share and aiming to close later this year pending approvals. Penumbra’s portfolio spans neurovascular and vascular devices, including thrombectomy systems, potentially broadening Boston Scientific’s growth in high-potential markets. Financing consists of roughly 73% cash and 27% stock, with an expected near-term EPS dilution followed by accretion as synergies materialize.







